Long-acting antipsychotics and mortality in patients with schizophrenia receiving homecare case management.

IF 6.2 3区 医学 Q1 CLINICAL NEUROLOGY
Wen-Yin Chen, Po-Yu Chen, Chih-Chiang Chiu, Chun-Hung Pan, Sheng-Siang Su, Chiao-Chicy Chen, Chian-Jue Kuo
{"title":"Long-acting antipsychotics and mortality in patients with schizophrenia receiving homecare case management.","authors":"Wen-Yin Chen, Po-Yu Chen, Chih-Chiang Chiu, Chun-Hung Pan, Sheng-Siang Su, Chiao-Chicy Chen, Chian-Jue Kuo","doi":"10.1111/pcn.13853","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Long-acting injectable antipsychotics (LAIs) offer several advantages over oral antipsychotic medications for treating schizophrenia. However, whether the benefits of LAIs extend to patients receiving homecare case management (CM) remains unclear.</p><p><strong>Methods: </strong>This cohort study used Taiwan's National Health Insurance Research Database, enrolling 19,680 nationwide patients with schizophrenia who began homecare CM between January 1, 2000, and December 31, 2019. Each patient was followed for 5 years or to the data censored, with 30-day periods serving as follow-up units. We evaluated LAI and other medication usage during each period and their associations with mortality outcomes. Additionally, we investigated whether consistent users of homecare CM services (maintenance group) receiving specific LAI treatments had better prognoses.</p><p><strong>Results: </strong>In the cohort (n = 19,680), 6428 received first-generation antipsychotic long-acting injectables (FGA-LAIs) and 4954 received second-generation antipsychotic long-acting injectables (SGA-LAIs). The FGA-LAI group had a mean age of 39.27 years (55.13% male), while the SGA-LAI group had a mean age of 41.25 years (53.75% male). Of 1366 deaths within 5 years, 980 were from natural causes and 254 from suicide. FGA-LAIs reduced natural mortality (HR: 0.67, P = 0.001) but increased suicide risk (HR: 1.52, P = 0.01). SGA-LAIs lowered all-cause (HR: 0.53, P < 0.001) and natural mortality (HR: 0.42, P < 0.001) without affecting suicide mortality (HR: 0.82, P = 0.384). In the maintenance group, FGA-LAIs showed no mortality benefit and increased suicide risk (HR: 2.07, P < 0.001), while SGA-LAIs consistently reduced all-cause (HR: 0.39, P < 0.001), natural (HR: 0.31, P < 0.001), and suicide mortality (HR: 0.54, P = 0.034).</p><p><strong>Conclusions: </strong>SGA-LAIs could be a preferable treatment for reducing mortality in patients with schizophrenia receiving homecare CM, particularly for those in the maintenance group.</p>","PeriodicalId":20938,"journal":{"name":"Psychiatry and Clinical Neurosciences","volume":" ","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry and Clinical Neurosciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pcn.13853","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Long-acting injectable antipsychotics (LAIs) offer several advantages over oral antipsychotic medications for treating schizophrenia. However, whether the benefits of LAIs extend to patients receiving homecare case management (CM) remains unclear.

Methods: This cohort study used Taiwan's National Health Insurance Research Database, enrolling 19,680 nationwide patients with schizophrenia who began homecare CM between January 1, 2000, and December 31, 2019. Each patient was followed for 5 years or to the data censored, with 30-day periods serving as follow-up units. We evaluated LAI and other medication usage during each period and their associations with mortality outcomes. Additionally, we investigated whether consistent users of homecare CM services (maintenance group) receiving specific LAI treatments had better prognoses.

Results: In the cohort (n = 19,680), 6428 received first-generation antipsychotic long-acting injectables (FGA-LAIs) and 4954 received second-generation antipsychotic long-acting injectables (SGA-LAIs). The FGA-LAI group had a mean age of 39.27 years (55.13% male), while the SGA-LAI group had a mean age of 41.25 years (53.75% male). Of 1366 deaths within 5 years, 980 were from natural causes and 254 from suicide. FGA-LAIs reduced natural mortality (HR: 0.67, P = 0.001) but increased suicide risk (HR: 1.52, P = 0.01). SGA-LAIs lowered all-cause (HR: 0.53, P < 0.001) and natural mortality (HR: 0.42, P < 0.001) without affecting suicide mortality (HR: 0.82, P = 0.384). In the maintenance group, FGA-LAIs showed no mortality benefit and increased suicide risk (HR: 2.07, P < 0.001), while SGA-LAIs consistently reduced all-cause (HR: 0.39, P < 0.001), natural (HR: 0.31, P < 0.001), and suicide mortality (HR: 0.54, P = 0.034).

Conclusions: SGA-LAIs could be a preferable treatment for reducing mortality in patients with schizophrenia receiving homecare CM, particularly for those in the maintenance group.

接受家庭护理病例管理的精神分裂症患者的长效抗精神病药物和死亡率。
目的:长效注射抗精神病药物(LAIs)在治疗精神分裂症方面比口服抗精神病药物有几个优点。然而,LAIs的好处是否延伸到接受家庭护理病例管理(CM)的患者仍不清楚。​每例患者随访5年或至资料截留为止,随访时间为30天。我们评估了每个时期的LAI和其他药物使用情况及其与死亡率结果的关系。此外,我们调查了接受特定LAI治疗的家庭护理CM服务(维持组)的一贯用户是否有更好的预后。结果:在队列中(n = 19680), 6428人接受了第一代抗精神病长效注射剂(FGA-LAIs), 4954人接受了第二代抗精神病长效注射剂(SGA-LAIs)。FGA-LAI组平均年龄39.27岁(男性占55.13%),SGA-LAI组平均年龄41.25岁(男性占53.75%)。在5年内死亡的1366人中,980人死于自然原因,254人死于自杀。FGA-LAIs降低了自然死亡率(HR: 0.67, P = 0.001),但增加了自杀风险(HR: 1.52, P = 0.01)。结论:SGA-LAIs可能是一种较好的治疗方法,可以降低接受家庭护理CM的精神分裂症患者的死亡率,尤其是维持组。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.40
自引率
4.20%
发文量
181
审稿时长
6-12 weeks
期刊介绍: PCN (Psychiatry and Clinical Neurosciences) Publication Frequency: Published 12 online issues a year by JSPN Content Categories: Review Articles Regular Articles Letters to the Editor Peer Review Process: All manuscripts undergo peer review by anonymous reviewers, an Editorial Board Member, and the Editor Publication Criteria: Manuscripts are accepted based on quality, originality, and significance to the readership Authors must confirm that the manuscript has not been published or submitted elsewhere and has been approved by each author
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信